Products
Solid Tumors
Pan-Cancer
Cancer Type-Specific
Minimal Residual Disease
Hematologic Malignancies
Pan-Cancer
Cancer Type-Specific
Cancer Early Detection
Hereditary Cancers
Services
Central Lab Testing
Local Testing Solutions
IVD Kit Solutions
RUO Kit Solutions
Research Services
DNA Sequencing
RNA Sequencing
Technology
Our Technology
Publications
Partnerships
About Us
What is Precision Oncology?
Our Company
Our Team
Certificates & Accreditation
News
Newsroom
Geneseeq Blogs
Join Us
Contact Us
Search
November 10, 2025
Geneseeq Receives NMPA Approval for PanTRKare™ – China’s First NGS-Based Pan-Solid Tumor Companion Diagnostic Kit for NTRK Gene Fusions
by GENESEEQ
September 29, 2025
Geneseeq Validates Cell-free DNA Blood Test for Early Detection of Pancreatic Cancer in a Prospective Study
by GENESEEQ
September 2, 2025
GeneseeqPrime® Gains FDA 510(k) Clearance
by GENESEEQ
May 28, 2025
Geneseeq’s Breakthrough Cancer Detection Blood Test Published in Nature Medicine
by GENESEEQ
January 3, 2024
FDA Grants Breakthrough Device Designation for Geneseeq’s Multi-cancer Early Detection Solution
by GENESEEQ
Privacy Preference Center
Privacy Preferences
×
